Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Equity Average (2016 - 2025)

Historic Equity Average for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Q3 2025 value amounting to -$286.2 million.

  • Ironwood Pharmaceuticals' Equity Average rose 959.5% to -$286.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.2 million, marking a year-over-year increase of 959.5%. This contributed to the annual value of -$323.8 million for FY2024, which is 31158.64% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Equity Average stood at -$286.2 million for Q3 2025, which was up 959.5% from -$321.1 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Equity Average ranged from a high of $679.6 million in Q1 2023 and a low of -$338.4 million during Q1 2024
  • Its 5-year average for Equity Average is $93.8 million, with a median of $86.4 million in 2021.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 362752.04% in 2021, then crashed by 28114.14% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Equity Average (Quarter) stood at $592.9 million in 2021, then grew by 4.86% to $621.7 million in 2022, then tumbled by 154.04% to -$336.0 million in 2023, then grew by 8.83% to -$306.3 million in 2024, then rose by 6.59% to -$286.2 million in 2025.
  • Its Equity Average was -$286.2 million in Q3 2025, compared to -$321.1 million in Q2 2025 and -$317.7 million in Q1 2025.